Core Viewpoint - 尚荣医疗's stock closed at 3.84 yuan, down 2.29%, with a rolling PE ratio of 145.18 times, and a total market value of 3.247 billion yuan [1] Company Overview - Shenzhen 尚荣医疗股份有限公司 specializes in the production and sales of medical products, medical services, and health industry operations [1] - The company is one of the earliest to introduce clean technology into hospital operating rooms in China [1] - 尚荣医疗 has received numerous honors, including national key new product recognition and awards from the Shenzhen municipal government for technological progress [1] - The company holds over 180 patents, which are a key driver of its continuous development [1] Financial Performance - In Q1 2025, the company reported operating revenue of 280 million yuan, a year-on-year increase of 30% [2] - Net profit for the same period was 13.9642 million yuan, reflecting a year-on-year growth of 0.58% [2] - The sales gross margin stood at 15.27% [2] Industry Comparison - The average PE ratio for the medical device industry is 53.93 times, with a median of 37.81 times, placing 尚荣医疗 at 111th in the industry ranking [1][2] - The company's PE (TTM) is significantly higher than the industry average, indicating potential overvaluation [2]

Core Viewpoint - The stock of Shangrong Medical (002551) has experienced a decline, with significant net outflow of funds from major investors, indicating potential concerns about the company's performance and market sentiment [1][2]. Group 1: Stock Performance - As of August 6, 2025, Shangrong Medical's stock closed at 3.84 yuan, down 2.29% with a turnover rate of 4.92% and a trading volume of 300,600 hands, resulting in a transaction amount of 116 million yuan [1]. - In the past five days, the stock has shown fluctuating performance, with a notable drop on August 5, where it closed at 3.93 yuan, down 0.51% [2]. Group 2: Fund Flow Analysis - On August 6, 2025, the net outflow of major funds was 16.38 million yuan, accounting for 14.09% of the total transaction amount, while retail investors saw a net inflow of 13.93 million yuan, representing 11.98% of the total [1][2]. - Over the past five days, major funds have consistently shown net outflows, with the highest outflow recorded on August 5 at 27.59 million yuan, indicating a trend of reduced confidence among institutional investors [2]. Group 3: Financial Metrics - Shangrong Medical's total market capitalization is 3.247 billion yuan, with a net asset value of 2.789 billion yuan and a net profit of 13.96 million yuan, which is significantly lower than the industry averages [3]. - The company's gross margin stands at 15.27%, while the industry average is 51.31%, highlighting a substantial gap in profitability compared to peers [3]. - The first quarter of 2025 reported a main business revenue of 280 million yuan, a year-on-year increase of 1.3%, and a net profit attributable to shareholders of 13.96 million yuan, reflecting a modest growth trajectory [3].

8月4日，尚荣医疗今日收盘3.95元，上涨1.28%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到149.34倍，创17天以来新低，总市值33.40亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均54.31倍，行业中值38.11倍，尚荣医疗排 名第110位。 股东方面，截至2025年3月31日，尚荣医疗股东户数58323户，较上次减少621户，户均持股市值35.28万 元，户均持股数量2.76万股。 深圳市尚荣医疗股份有限公司的主营业务是医疗产品生产销售、医疗服务、健康产业运营等。公司的主 要产品是医疗服务、医疗产品生产销售、健康产业运营。公司是国内最早将洁净技术引入医院手术部的 企业之一，公司的智能自控手术室产品荣获国家科技部、商务部、质量监督总局及环保总局颁发的国家 重点新产品荣誉，荣获深圳市人民政府颁发的科学技术进步二等奖，荣获深圳市科技和信息局颁发的高 新技术项目。公司是国家级高新技术企业、深圳市自主创新行业领军企业之一、深圳市高新技术企业、 深圳市知识产权优势企业。公司及子公司累计获得超过180项专利，成为公司持续发展的源动力。 最新一期业绩显示，2025年一季报，公司 ...

Group 1 - The stock price of Shangrong Medical (002551) closed at 3.9 yuan on August 1, 2025, with an increase of 2.9% and a turnover rate of 6.25% [1] - The company reported a total revenue of 280 million yuan for Q1 2025, representing a year-on-year growth of 1.3%, and a net profit attributable to shareholders of 13.96 million yuan, up 0.58% year-on-year [1] - The company's non-recurring net profit reached 11.70 million yuan, showing a significant year-on-year increase of 84.75% [1] Group 2 - Shangrong Medical has made investments in 17 companies and participated in 52 bidding projects [2] - The company holds 9 trademark registrations and 121 patents, along with 41 administrative licenses [2] - Shangrong Medical was established in 1998 and is primarily engaged in the manufacturing of specialized equipment [1][2]

序号股票简称PE(TTM)PE(静)市净率总市值(元)13尚荣医疗147.45147.991.2532.97亿行业平均 53.6550.024.68114.74亿行业中值37.2237.112.6755.30亿1九安医疗11.0111.130.87185.78亿2英科医疗 15.4516.651.37244.06亿3新华医疗15.7214.571.28100.77亿4山东药玻16.0216.071.84151.57亿5振德医疗 16.2915.351.0459.13亿6奥美医疗16.4116.081.6959.27亿7九强生物17.4416.212.1486.36亿8康德莱 17.6117.631.4637.96亿9维力医疗17.6918.902.2341.47亿10奥泰生物18.1519.141.4757.89亿11鱼跃医疗 19.8419.462.68351.37亿12安图生物20.0619.152.58228.74亿 股东方面，截至2025年3月31日，尚荣医疗股东户数58323户，较上次减少621户，户均持股市值35.28万 元，户均持股数量2.76万股。 来源：金融界 8月1日，尚荣医疗今日收盘3. ...

深圳市尚荣医疗股份有限公司的主营业务是医疗产品生产销售、医疗服务、健康产业运营等。公司的主 要产品是医疗服务、医疗产品生产销售、健康产业运营。公司是国内最早将洁净技术引入医院手术部的 企业之一，公司的智能自控手术室产品荣获国家科技部、商务部、质量监督总局及环保总局颁发的国家 重点新产品荣誉，荣获深圳市人民政府颁发的科学技术进步二等奖，荣获深圳市科技和信息局颁发的高 新技术项目。公司是国家级高新技术企业、深圳市自主创新行业领军企业之一、深圳市高新技术企业、 深圳市知识产权优势企业。公司及子公司累计获得超过180项专利，成为公司持续发展的源动力。 最新一期业绩显示，2025年一季报，公司实现营业收入2.80亿元，同比1.30%；净利润1396.42万元，同 比0.58%，销售毛利率15.27%。 来源：金融界 7月29日，尚荣医疗今日收盘3.8元，下跌1.30%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到143.67倍，总市值32.13亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均55.46倍，行业中值37.74倍，尚荣医疗排 名第109位。 股东方面，截至2025年3月31日， ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Shangrong Medical, indicating a high PE ratio compared to industry averages [1][2] - As of July 22, Shangrong Medical's stock closed at 3.82 yuan, with a PE ratio of 144.43, significantly higher than the industry average of 53.47 [1] - The company has experienced a net outflow of 279.90 thousand yuan in principal funds on July 22, with a total outflow of 1,735.96 thousand yuan over the past five days [1] Group 2 - In the latest quarterly report for Q1 2025, the company reported revenue of 280 million yuan, a year-on-year increase of 130%, and a net profit of 13.96 million yuan, a year-on-year increase of 0.58% [2] - The company's gross profit margin stands at 15.27% [2] - Shangrong Medical is recognized as a national high-tech enterprise and has received numerous awards and honors, including over 180 patents, which contribute to its ongoing development [1]

Performance Forecast - The company expects a net loss of between 7 million and 9.5 million yuan for the current reporting period, compared to a profit of 14.0266 million yuan in the same period last year, representing a decline of 149.91% to 167.73% [1] - The net loss after deducting non-recurring gains and losses is projected to be between 11.6594 million and 14.1594 million yuan, compared to a profit of 2.3089 million yuan last year, indicating a decline of 604.98% to 713.25% [1] - Basic earnings per share are expected to be a loss of 0.008 to 0.011 yuan per share, compared to a profit of 0.0166 yuan per share in the previous year [1] Reasons for Performance Change - The revenue from completed medical engineering projects has decreased by 72% compared to the same period last year [1] - Sales volume and profit margin of exported medical consumables have further declined [1] - Government subsidies and other income from write-offs have decreased by approximately 90% compared to the same period last year, contributing to the overall loss [1]

Core Viewpoint - Shenzhen Shangrong Medical Co., Ltd. has corrected its half-year performance forecast for 2025, indicating a significant expected loss compared to the previous year [1][2][3] Summary by Relevant Sections Performance Forecast - The company expects a net loss of between 7 million and 9.5 million yuan for the current reporting period, compared to a profit of 14.0266 million yuan in the same period last year [1] - The net profit attributable to shareholders is projected to decline by 149.91% to 167.73% compared to the previous year [1] - The loss after deducting non-recurring gains and losses is estimated to be between 11.6594 million and 14.1594 million yuan, with a significant decline of 604.98% to 713.25% compared to the previous year [1] - Basic earnings per share are expected to be a loss of 0.008 yuan to 0.011 yuan, compared to a profit of 0.0166 yuan per share in the previous year [1]

证券代码：002551 证券简称：尚荣医疗 公告编号：2025-038 深圳市尚荣医疗股份有限公司 更正公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 深圳市尚荣医疗股份有限公司（以下简称"公司"）于2025年7月12日披露 的《2025年半年度业绩预告》（公告编号：2025-037）。因工作人员疏忽，上述 公告中的部分内容出现了错误，现予以更正。本次更正不涉及对原公告的实质性 的变更，具体如下： 更正前： 一、本期业绩预计情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 6 月 30 日。 （二）业绩预告情况 预计净利润为负值 | 项 目 | 本报告期 | | | 上年同期 | | | --- | --- | --- | --- | --- | --- | | 归属于上市公司 股东的净利润 | 亏损：700 | 万元— 950 | 万元 | 盈利：1402.66 | 万元 | | | 比上年同期下降：135.65 %—167.73 % | | | | | | 扣除非经常性损 益后的净利润 | 亏损：965.94 | 万元—1415 ...